However, recent studies investigating gene expression signatures, predicting the efficacy of PD-1/PD-L1 inhibitors in different cancer types, found that tumors with EMT or the mesenchymal phenotype showed a lower response rate [83,84,85]. This evidence concerns the gene CD274 and cancer.